Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles.

@article{Freise2012NaloxoneRO,
  title={Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles.},
  author={Kevin J Freise and G. C. Newbound and Christopher R. Tudan and Terrence P Clark},
  journal={Journal of veterinary pharmacology and therapeutics},
  year={2012},
  volume={35 Suppl 2},
  pages={
          45-51
        }
}
Opioid overdose in dogs is manifested by clinical signs such as excessive sedation, bradycardia, and hypothermia. The ability of two different intramuscular (i.m.) naloxone reversal regimens to reverse the opioid-induced effects of a fivefold overdose of long-acting transdermal fentanyl solution was evaluated in dogs. Twenty-four healthy Beagles were administered a single 13 mg/kg dose (fivefold overdose) of transdermal fentanyl solution and randomized to two naloxone reversal regimen treatment… 
View on PubMed
nexcyon.com
22 Citations
Background Citations
7
Methods Citations
4
Results Citations
2

22 Citations

Citation Type

Citation Type

Effect of three doses of nalbuphine on reversal of sedation and cardiopulmonary effects of morphine-acepromazine in healthy dogs.
The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogs.
TLDR
The recent approval of long-acting transdermal fentanyl solution for dogs provides a new approach for sustained delivery of fentanyl for the control of postoperative pain in dogs and mitigates the disadvantages of oral, parenteral, and patch-delivered opioids.
PHARMACOKINETIC EVALUATION OF A LONG-ACTING FENTANYL SOLUTION AFTER TRANSDERMAL ADMINISTRATION IN HELMETED GUINEAFOWL (NUMIDA MELEAGRIS)
TLDR
A single topical dose of 5 mg/kg appears to be safe for use in this species and maintained plasma concentrations above those reported to be analgesic in dogs for at least 7 days.
The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study.
TLDR
This long-acting fentanyl formulation provides veterinarians with a novel, registered option for the control of postoperative pain in dogs that improves dosing compliance and potentially mitigates the disadvantages of oral, parenteral, and patch delivered opioids.
The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study
TLDR
It was concluded that a single administration of TFS was safe and noninferior to repeated injections of oxymorphone for the control of postoperative pain over 4 days at the dose rates of both formulations used in this study.
Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs.
TLDR
The pharmacokinetics of a novel, long-acting transdermal fentanyl solution that delivers sustained plasma fentanyl concentrations following a single application for the control of postoperative pain in dogs were evaluated in healthy laboratory dogs and gave results consistent with laboratory PK studies in healthy dogs.
Higher doses of naloxone are needed in the synthetic opiod era
  • R. Moss, D. Carlo
  • Biology, Medicine
    Substance Abuse Treatment, Prevention, and Policy
  • 2019
TLDR
It is proposed that higher doses of naloxone are needed to combat the new era of overdoses due to the more potent synthetic opioids such as fentanyl.
Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection.
TLDR
These studies were designed to test the feasibility of using the hollow microneedle array as an effective method of naloxone and nalmefene delivery for emergency treatment of opioid-induced respiratory depression (OIRD).
Clinical Update: The Risk of Opioid Toxicity and Naloxone Use in Operational K9s.
  • L. Palmer, A. Gautier
  • Medicine, Psychology
    Journal of special operations medicine : a peer reviewed journal for SOF medical professionals
  • 2018
TLDR
The potential risks associated with opioid exposure as well as the use of naloxone as it pertains to the OpK9 are described.
Postanaesthetic pulmonary oedema in a dog following intravenous naloxone administration after upper airway surgery
TLDR
This is the first report of a dog developing pulmonary oedema following intravenous naloxone following intraoperative analgesia, in a cavalier King Charles spaniel anaesthetised for upper airway surgery.
...
1
2
3
...

References

SHOWING 1-10 OF 24 REFERENCES
Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison.
TLDR
Several pharmacokinetic/pharmacodynamic parameters of the two antagonists were comparable, however, nalmefene had a significantly more protracted terminal disposition and a significantly greater persistency in the biophase evaluated over the experimental time frame from 0 to 450 min.
The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogs.
TLDR
Data support the safe use of the 1× dose and describe the outcome of an overdose of up to 5× dose in the absence of opioid reversal, which was associated with a dose-limiting reduction in food and water intake and maintenance fluid replacement for the first 2 days following application.
Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
A novel, transdermal fentanyl solution (TFS) was developed that delivers sustained concentrations of fentanyl for days following a single application. The pharmacokinetics following a single topical…
Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
TLDR
The pharmacokinetics and bioequivalence results suggest that transdermal fentanyl solution could be applied as a single dose to the dorsal scapular area 2-4 h prior to surgery with analgesia lasting a minimum of 4 days.
The history and development of the fentanyl series.
  • T. Stanley
  • Medicine, Biology
    Journal of pain and symptom management
  • 1992
Transdermal fentanyl patches in small animals.
TLDR
In cats and dogs, transdermal fentanyl produced analgesia equivalent to intermittent butorphanol administration for up to 72 hours following patch application, except for the immediate 0- to 6-hour postoperative period.
Fentanyl's Analgesic, Respiratory, and Cardiovascular Actions in Relation to Dose and Plasma Concentration in Unanesthetized Dogs
TLDR
In dogs, fentanyl's analgesic action cannot be separated from its respiratory and cardiovascular effects, a phenomenon suggesting saturation of the opiate receptors.
Pharmacokinetics of naloxone and naltrexone in the dog.
TLDR
Although human and dog kinetics are similar for naloxone, naltrexone is long-acting in man, but is quickly dissipated in the dog.
Search for the “ideal analgesic” in pain treatment by engineering the mu‐opioid receptor
TLDR
This article decides to explore the possibility of using virus to deliver the mutant mu‐opioid receptor at the various sites of the nociceptive pathway and induce the antinocICEptive responses with the systemic administration of opioid antagonists.
Extended-duration agents for perioperative pain management
TLDR
This review discusses extended-and controlled-release agents administered perioperatively, which comprises MS Contin (Purdue Pharma LP, Stamford, CT), OxyContin (P Purdue Pharma LP), Opana ER (Endo Pharmaceuticals, Chadds Ford, PA), and DepoDur (EndO Pharmaceuticals).
...
1
2
3
...